LYCOS RETRIEVER 
Mylan Laboratories
built 655 days ago
Mylan Laboratories (NYSE:MYL) is one of the world's leading makers of generic drugs, providing 160 products in nearly 400 strengths, covering 46 therapeutic categories. The firm is active in the development and production of sophisticated dosage forms, such as transdermal patches, extended-release tablets and capsules. It is ... a leading supplier of unit dose pharmaceuticals to hospitals and other institutions. Customers include wholesalers, distributors, retail drugstore chains and government agencies. Competitors include Teva Pharmaceutical Industries (NASDAQ: TEVA) and Watson Pharmaceuticals (NYSE: WPI).
Source:
Mylan Laboratories Inc. is a leading pharmaceutical company which specializes in developing, manufacturing and marketing generic pharmaceuticals. Mylan is one of the world's leading manufacturers of prescription medicines overall, with over 140 generic products in approximately 360 product strengths, covering over 40 therapeutic areas. During the most recent fiscal year, Mylan shipped over 12.5 billion dosages, and over 200 million prescriptions were dispensed in the United States with Mylan products.
Source:
Mylan Inc., formerly Mylan Laboratories Inc. (Mylan), incorporated in 1970, is engaged in developing, licensing, manufacturing, marketing and distributing generic, brand and branded generic pharmaceutical products. The Company obtains new generic products primarily through internal product development. In addition, it licenses or co-develops products through arrangements with other companies. New generic product approvals are obtained from the United States Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) process, which requires the Company to demonstrate bioequivalence to a reference brand product. On January 8, 2007, the Company purchased 51.5% of Matrix Laboratories Limited (Matrix). Matrix is primarily engaged in the manufacture of active pharmaceutical ingredients (API) and solid oral dosage products.
Source:
Mylan Laboratories Inc., a leading maker of generic drugs, said a federal court in Boston dismissed claims that the company improperly reported prices to the federal government. Separately, a federal judge in Pittsburgh ruled that Mylan infringed patents related to the cancer drug paclitaxel. The patents are owned by NaPro BioTherapeutics Inc. and licensed to Abbott Laboratories. A trial on Mylan's contention that the patents are invalid could go to trial later this year. The Boston ruling involves a consolidated lawsuit against the pharmaceutical industry by consumers, health plans and state attorneys general who say the drug companies tell the government that they charge doctors more than they do, inflating reimbursements. The government uses so-called average wholesale prices to set reimbursements from federal health programs.
Source:
Mylan Laboratories (Mylan) is engaged in developing, licensing, manufacturing, marketing and distributing generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients. The company primarily operates in the US. It is headquartered in Canonsburg, Pennsylvania, and employs about 6,400 people.
Source:
MORE ABOUT
Mylan Laboratories